Bacterial Vaccines Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Vaccine Type, By Patient Age Group, By Distribution Channel, By Route of Administration, By Region & Competition, 2020-2030F

Description

Global Bacterial Vaccines Market was valued at USD 7.10 billion in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 7.20% through 2030. Bacterial vaccines, also known as bacterial immunizations or bacterial vaccines, are a type of preventive medicine designed to stimulate the body's immune system to recognize and fight against specific bacterial pathogens. These vaccines are created using components of bacteria or inactivated bacterial cells to provide immunity against various bacterial infections. Bacterial vaccines are crucial for preventing a wide range of bacterial infections that can cause serious illnesses, complications, and even death. Common bacterial diseases prevented by vaccines include tetanus, diphtheria, pertussis, pneumonia, and meningitis.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 7.10 Billion
Market Size 2030	USD 10.69 Billion
CAGR 2025-2030	7.20%
Fastest Growing Segment	Injectable Vaccines
Largest Market	North America

Widespread vaccination with bacterial vaccines not only protects vaccinated individuals but also contributes to herd immunity. This indirectly protects those who cannot receive vaccines due to medical reasons, such as individuals with certain health conditions or weakened immune systems. Bacterial vaccines play a critical role in global health efforts, especially in low- and middle-income countries. Vaccination programs reduce the burden of bacterial diseases, improve child survival rates, and enhance overall public health. For instance, according to the Centers for Disease Control and Prevention (CDC) in 2025, outbreaks resulted in 75,968 reported human cases and 4,235 deaths, highlighting the significant impact of infectious disease spread.

Key Market Drivers

Emerging Infectious Diseases

Emerging Infectious Diseases (EIDs) are diseases that have recently appeared in a population or have existed but are rapidly increasing in incidence or geographic range. These diseases often pose a significant threat to public health because they are novel, poorly understood, and may lack effective treatments. Bacterial EIDs can include diseases caused by antibiotic-resistant strains or previously unrecognized pathogens. Bacterial vaccines are crucial tools for the prevention and control of emerging bacterial infections. They provide a proactive approach to combat new threats by preparing populations with immunity against specific bacterial pathogens. In the event of an outbreak of an emerging bacterial infection, rapid vaccination campaigns can be implemented to contain the spread of the disease. This is particularly important in preventing large-scale epidemics or pandemics. For instance, according to WHO 2024, better vaccine use could cut antibiotic use by 2.5 billion doses annually, preventing deaths from antimicrobial resistance, reducing treatment costs, and curbing the spread of resistant infections.

Key Market Challenges

Vaccine Hesitancy

Vaccine hesitancy refers to the reluctance or refusal of individuals or communities to accept vaccines, despite the availability of vaccination services. This hesitancy can manifest for various reasons, including safety concerns, misinformation, and distrust of vaccines and healthcare systems. Vaccine hesitancy can lead to lower vaccination rates, which means that fewer individuals are protected against bacterial infections. This can result in pockets of susceptible individuals within a community, increasing the risk of disease outbreaks. Lower vaccine coverage due to hesitancy reduces the level of herd immunity within a population. This not only puts unvaccinated individuals at risk but also makes it easier for bacterial diseases to spread within the community. Vaccine hesitancy can impede public health efforts to control bacterial infections. Diseases that were once well-controlled can experience resurgence when vaccine coverage declines. A rise in vaccine-preventable diseases due to hesitancy can strain healthcare systems, leading to increased healthcare costs associated with treating these diseases and their complications. Governments and healthcare organizations must allocate resources to combat vaccine hesitancy through public health campaigns, educational initiatives, and outreach efforts. These resources could be used elsewhere if hesitancy was not a factor. Reduced demand for bacterial vaccines may affect funding for research and development of new vaccines and improvements to existing ones. Pharmaceutical companies may be less motivated to invest in vaccine development if there is lower demand. The spread of misinformation and vaccine-related myths on social media platforms can contribute to vaccine hesitancy. False information can erode public trust in vaccines and healthcare providers. Safety concerns, whether founded in evidence or not, can lead to hesitancy. High-profile vaccine safety scares can have lasting effects on public perception.

Key Market Trends

Pipeline Developments

Pharmaceutical companies and research institutions are actively working on expanding their portfolio of bacterial vaccines. This includes developing vaccines for a wide range of bacterial pathogens responsible for various infectious diseases. The emergence of new bacterial pathogens or the reemergence of existing ones often prompts the development of vaccines to address these threats. Recent examples include vaccine development efforts in response to antibiotic-resistant strains of bacteria. Advances in vaccine technology, including the use of novel adjuvants, recombinant DNA technology, and conjugate vaccine platforms, are driving innovation in bacterial vaccine development. These technologies can improve vaccine efficacy and safety. Research is focused on developing highly targeted vaccines that are effective against specific bacterial strains or serotypes. Precision in vaccine design is important for combating antibiotic-resistant bacteria. Some pipeline developments involve multivalent vaccines that target multiple bacterial strains or serotypes in a single vaccine formulation. This can simplify vaccination schedules and improve coverage. International organizations and governments are supporting vaccine research and development for bacterial diseases that disproportionately affect low- and middle-income countries. These initiatives are aimed at reducing global health disparities. Recent pandemics, such as COVID-19, have highlighted the importance of vaccine development for emerging infectious diseases, including those caused by bacterial pathogens. Preparedness efforts include research into rapid vaccine development platforms.

Key Market Players

Pfizer Inc.
GSK plc
Novartis AG
Mylan N.V.
Sanofi SA
Boehringer Ingelheim International GmbH.
Merck & Co., Inc.
F. Hoffmann-La Roche Ltd.
Bristol-Myers Squibb Company
Bharat Biotech International Ltd
Serum Institute of India Pvt. Ltd

Report Scope:

In this report, the Global Bacterial Vaccines Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Bacterial Vaccines Market, By Vaccine Type:

Pertussis (Whooping Cough) Vaccines
Tetanus Vaccines
Diphtheria Vaccines
Pneumococcal Vaccines
Meningococcal Vaccines
Typhoid Vaccines
Tuberculosis (TB) Vaccines
Cholera Vaccines
Shigellosis Vaccines
Others

Bacterial Vaccines Market, By Patient Age Group:

Pediatric Vaccines (Infants, Children)
Adolescent Vaccines
Adult Vaccines
Geriatric Vaccines

Bacterial Vaccines Market, By Distribution Channel:

Government Agencies and Programs
Hospitals and Clinics
Retail Pharmacies
Online Pharmacies
Others

Bacterial Vaccines Market, By Route of Administration:

Injectable Vaccines
Oral Vaccines
Nasal Vaccines

Bacterial Vaccines Market, By region:

North America
- United States
- Canada
- Mexico
Asia-Pacific
- China
- India
- South Korea
- Australia
- Japan
Europe
- Germany
- France
- United Kingdom
- Spain
- Italy
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Bacterial Vaccines Market.

Available Customizations:

Global Bacterial Vaccines Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Bacterial Vaccines Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Vaccine Type (Pertussis (Whooping Cough) Vaccines, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis (TB) Vaccines, Cholera Vaccines, Shigellosis Vaccines, Others)
- 5.2.2. By Patient Age Group (Pediatric Vaccines (Infants, Children), Adolescent Vaccines, Adult Vaccines, Geriatric Vaccines)
- 5.2.3. By Distribution Channel (Government Agencies and Programs, Hospitals and Clinics, Retail Pharmacies, Online Pharmacies, Others)
- 5.2.4. By Route of Administration (Injectable Vaccines, Oral Vaccines, Nasal Vaccines)
- 5.2.5. By Region
- 5.2.6. By Company (2024)
5.3. Market Map

6. Asia Pacific Bacterial Vaccines Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Vaccine Type
- 6.2.2. By Patient Age Group
- 6.2.3. By Distribution Channel
- 6.2.4. By Route of Administration
- 6.2.5. By Country
6.3. Asia Pacific: Country Analysis
- 6.3.1. China Bacterial Vaccines Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Vaccine Type
    - 6.3.1.2.2. By Patient Age Group
    - 6.3.1.2.3. By Distribution Channel
    - 6.3.1.2.4. By Route of Administration
- 6.3.2. India Bacterial Vaccines Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Vaccine Type
    - 6.3.2.2.2. By Patient Age Group
    - 6.3.2.2.3. By Distribution Channel
    - 6.3.2.2.4. By Route of Administration
- 6.3.3. Australia Bacterial Vaccines Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Vaccine Type
    - 6.3.3.2.2. By Patient Age Group
    - 6.3.3.2.3. By Distribution Channel
    - 6.3.3.2.4. By Route of Administration
- 6.3.4. Japan Bacterial Vaccines Market Outlook
  - 6.3.4.1. Market Size & Forecast
    - 6.3.4.1.1. By Value
  - 6.3.4.2. Market Share & Forecast
    - 6.3.4.2.1. By Vaccine Type
    - 6.3.4.2.2. By Patient Age Group
    - 6.3.4.2.3. By Distribution Channel
    - 6.3.4.2.4. By Route of Administration
- 6.3.5. South Korea Bacterial Vaccines Market Outlook
  - 6.3.5.1. Market Size & Forecast
    - 6.3.5.1.1. By Value
  - 6.3.5.2. Market Share & Forecast
    - 6.3.5.2.1. By Vaccine Type
    - 6.3.5.2.2. By Patient Age Group
    - 6.3.5.2.3. By Distribution Channel
    - 6.3.5.2.4. By Route of Administration

7. Europe Bacterial Vaccines Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Vaccine Type
- 7.2.2. By Patient Age Group
- 7.2.3. By Distribution Channel
- 7.2.4. By Route of Administration
- 7.2.5. By Country
7.3. Europe: Country Analysis
- 7.3.1. France Bacterial Vaccines Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Vaccine Type
    - 7.3.1.2.2. By Patient Age Group
    - 7.3.1.2.3. By Distribution Channel
    - 7.3.1.2.4. By Route of Administration
- 7.3.2. Germany Bacterial Vaccines Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Vaccine Type
    - 7.3.2.2.2. By Patient Age Group
    - 7.3.2.2.3. By Distribution Channel
    - 7.3.2.2.4. By Route of Administration
- 7.3.3. Spain Bacterial Vaccines Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Vaccine Type
    - 7.3.3.2.2. By Patient Age Group
    - 7.3.3.2.3. By Distribution Channel
    - 7.3.3.2.4. By Route of Administration
- 7.3.4. Italy Bacterial Vaccines Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Vaccine Type
    - 7.3.4.2.2. By Patient Age Group
    - 7.3.4.2.3. By Distribution Channel
    - 7.3.4.2.4. By Route of Administration
- 7.3.5. United Kingdom Bacterial Vaccines Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Vaccine Type
    - 7.3.5.2.2. By Patient Age Group
    - 7.3.5.2.3. By Distribution Channel
    - 7.3.5.2.4. By Route of Administration

8. North America Bacterial Vaccines Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Vaccine Type
- 8.2.2. By Patient Age Group
- 8.2.3. By Distribution Channel
- 8.2.4. By Route of Administration
- 8.2.5. By Country
8.3. North America: Country Analysis
- 8.3.1. United States Bacterial Vaccines Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Vaccine Type
    - 8.3.1.2.2. By Patient Age Group
    - 8.3.1.2.3. By Distribution Channel
    - 8.3.1.2.4. By Route of Administration
- 8.3.2. Mexico Bacterial Vaccines Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Vaccine Type
    - 8.3.2.2.2. By Patient Age Group
    - 8.3.2.2.3. By Distribution Channel
    - 8.3.2.2.4. By Route of Administration
- 8.3.3. Canada Bacterial Vaccines Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Vaccine Type
    - 8.3.3.2.2. By Patient Age Group
    - 8.3.3.2.3. By Distribution Channel
    - 8.3.3.2.4. By Route of Administration

9. South America Bacterial Vaccines Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Vaccine Type
- 9.2.2. By Patient Age Group
- 9.2.3. By Distribution Channel
- 9.2.4. By Route of Administration
- 9.2.5. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Bacterial Vaccines Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Vaccine Type
    - 9.3.1.2.2. By Patient Age Group
    - 9.3.1.2.3. By Distribution Channel
    - 9.3.1.2.4. By Route of Administration
- 9.3.2. Argentina Bacterial Vaccines Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Vaccine Type
    - 9.3.2.2.2. By Patient Age Group
    - 9.3.2.2.3. By Distribution Channel
    - 9.3.2.2.4. By Route of Administration
- 9.3.3. Colombia Bacterial Vaccines Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Vaccine Type
    - 9.3.3.2.2. By Patient Age Group
    - 9.3.3.2.3. By Distribution Channel
    - 9.3.3.2.4. By Route of Administration

10. Middle East and Africa Bacterial Vaccines Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Vaccine Type
- 10.2.2. By Patient Age Group
- 10.2.3. By Distribution Channel
- 10.2.4. By Route of Administration
- 10.2.5. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Bacterial Vaccines Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Vaccine Type
    - 10.3.1.2.2. By Patient Age Group
    - 10.3.1.2.3. By Distribution Channel
    - 10.3.1.2.4. By Route of Administration
- 10.3.2. Saudi Arabia Bacterial Vaccines Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Vaccine Type
    - 10.3.2.2.2. By Patient Age Group
    - 10.3.2.2.3. By Distribution Channel
    - 10.3.2.2.4. By Route of Administration
- 10.3.3. UAE Bacterial Vaccines Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Vaccine Type
    - 10.3.3.2.2. By Patient Age Group
    - 10.3.3.2.3. By Distribution Channel
    - 10.3.3.2.4. By Route of Administration

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions

13. Global Bacterial Vaccines Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

16.1. Pfizer Inc.
- 16.1.1. Business Overview
- 16.1.2. Company Snapshot
- 16.1.3. Products & Services
- 16.1.4. Financials (In case of listed companies)
- 16.1.5. Recent Developments
- 16.1.6. SWOT Analysis
16.2. GSK plc
- 16.2.1. Business Overview
- 16.2.2. Company Snapshot
- 16.2.3. Products & Services
- 16.2.4. Financials (In case of listed companies)
- 16.2.5. Recent Developments
- 16.2.6. SWOT Analysis
16.3. Novartis AG
- 16.3.1. Business Overview
- 16.3.2. Company Snapshot
- 16.3.3. Products & Services
- 16.3.4. Financials (In case of listed companies)
- 16.3.5. Recent Developments
- 16.3.6. SWOT Analysis
16.4. Mylan N.V.
- 16.4.1. Business Overview
- 16.4.2. Company Snapshot
- 16.4.3. Products & Services
- 16.4.4. Financials (In case of listed companies)
- 16.4.5. Recent Developments
- 16.4.6. SWOT Analysis
16.5. Sanofi SA
- 16.5.1. Business Overview
- 16.5.2. Company Snapshot
- 16.5.3. Products & Services
- 16.5.4. Financials (In case of listed companies)
- 16.5.5. Recent Developments
- 16.5.6. SWOT Analysis
16.6. Boehringer Ingelheim International GmbH.
- 16.6.1. Business Overview
- 16.6.2. Company Snapshot
- 16.6.3. Products & Services
- 16.6.4. Financials (In case of listed companies)
- 16.6.5. Recent Developments
- 16.6.6. SWOT Analysis
16.7. Merck & Co., Inc.
- 16.7.1. Business Overview
- 16.7.2. Company Snapshot
- 16.7.3. Products & Services
- 16.7.4. Financials (In case of listed companies)
- 16.7.5. Recent Developments
- 16.7.6. SWOT Analysis
16.8. F. Hoffmann-La Roche Ltd.
- 16.8.1. Business Overview
- 16.8.2. Company Snapshot
- 16.8.3. Products & Services
- 16.8.4. Financials (In case of listed companies)
- 16.8.5. Recent Developments
- 16.8.6. SWOT Analysis
16.9. Bristol-Myers Squibb Company
- 16.9.1. Business Overview
- 16.9.2. Company Snapshot
- 16.9.3. Products & Services
- 16.9.4. Financials (In case of listed companies)
- 16.9.5. Recent Developments
- 16.9.6. SWOT Analysis
16.10.Bharat Biotech International Ltd
- 16.10.1. Business Overview
- 16.10.2. Company Snapshot
- 16.10.3. Products & Services
- 16.10.4. Financials (In case of listed companies)
- 16.10.5. Recent Developments
- 16.10.6. SWOT Analysis
16.11. Serum Institute of India Pvt. Ltd
- 16.11.1. Business Overview
- 16.11.2. Company Snapshot
- 16.11.3. Products & Services
- 16.11.4. Financials (In case of listed companies)
- 16.11.5. Recent Developments
- 16.11.6. SWOT Analysis